This marks the 4th PBPK publication by CPT‐PSP of the effect of CRS as a result of biologics‐treatment on co‐medications that are CYP substrates, after blinatumomab,2 mosunetuzumab,3 and glofitamab.4 The gene discussed is PPIG; the disease is congenital rubella syndrome.